Skip to content

Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection

Multimodal Data Prediction Based on Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05589480
Acronym
PaC
Enrollment
226
Registered
2022-10-21
Start date
2022-08-01
Completion date
2022-09-01
Last updated
2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

Recurrence of Pancreatic Cancer(PCa) is a multifactorial event. Based on the clinicopathological characteristics and imaging data of patients with PCa, the investigators used image processing and machine learning algorithms to build a more comprehensive and robust model, and added some unused features to explore its clinical application value. A retrospective analysis of patients with PCa who underwent radical resection at Zhejiang Cancer Hospital (Hangzhou, China) from January 2013 to December 2020. The database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing radical PCa surgery in the investigators' hospital. The investigators used the PyRadiomics platform to extract image features.

Interventions

OTHERpreoperative demographics, blood markers, surgical pathology information,and enhanced CT features.

preoperative demographics, blood markers, surgical pathology information,and enhanced CT features.

Sponsors

Luo Cong
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Have the results of enhanced CT examination of the pancreas within 1 month before surgery in our hospital; * Radical resection of pancreatic cancer was performed in our hospital; * There are follow-up results in our hospital, and the follow-up endpoints include disease recurrence or at least 12 months. * Complete clinical medical records and imaging data.

Exclusion criteria

* non-R0 resection; * Combined with other malignant tumors * The patient's imaging data has technical problems or the lesion is too small (less than 1cm), which is not suitable for omics analysis.

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival1 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026